

Manipulation of neuronal cell line NG108-15, as an *in vitro* model for investigating the role of schizophrenia candidate gene *ERBB4*

C. Paterson^{a,b}, B.J. Morris^{a,b}, J.A. Pratt^{a,c}, J. Storey^d and C.L. Winchester^{a,c}

^aPsyRING, West Medical Building, University of Glasgow, G12 8QQ, ^bInstitute of Biomedical and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ^cStrathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom, ^dSchizophrenia & Cognitive Disorders DPU, Neuroscience CEDD, GlaxoSmithKline, Harlow, United Kingdom, CM19 5AW
c.paterson.3@research.gla.ac.uk

INTRODUCTION

- Numerous genes and environmental factors play an important role in the susceptibility to schizophrenia, a psychiatric disorder that affects approximately 1% of the population worldwide.
- It is poorly understood what these factors are, how they function and interact in convergent signalling pathways resulting in such a polygenic disorder.
- ERBB4* is a strong candidate susceptibility gene for schizophrenia for several reasons including; positive genetic association in several populations^{1,2}, evidence of brain region specific differential expression in *post mortem* tissue from schizophrenia patients^{3,4} and its important roles in neurodevelopment⁵.
- Converging evidence is beginning to emerge; nonetheless, the pathophysiological role of *ERBB4* in schizophrenia is not yet fully established.
- Manipulation of neuronal cell lines allows the investigation of signalling pathways that may be affected in schizophrenia, such as the NRG1-ERBB4 pathway.

AIM

- To investigate the mouse neuroblastoma x rat glioma neuronal cell line NG108-15, as an appropriate *in vitro* model for the exploration of the Nrg1-ErbB4 signalling pathway by manipulating *ErbB4* expression and analysing the downstream effects.

METHODS

WESTERN BLOTTING- Total protein lysate, isolated from NG108-15 cells, was electrophoresed through Tris-HCL gel then blotted onto PVDF membrane which was subsequently probed with a primary antibody against ErbB4 and an anti-rabbit-HRP labelled secondary antibody (both Santa Cruz Biotechnology).

IMMUNOFLUORESCENCE- NG108-15 cells were plated onto poly-L-lysine coated chamber slides, fixed in 100% methanol, then labelled with antibody against ErbB4 and an anti-rabbit-alexa488 labelled secondary antibody (both Santa Cruz Biotechnology).


REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION (RT-PCR)- Total RNA was isolated from NG108-15 cells and first stand cDNA was synthesised (VILO™ Superscript®III, Invitrogen). *ErbB4* transcripts were amplified by PCR using forward and reverse PCR primers, designed specifically to the mouse or rat transcripts of *ErbB4* (Sigma Genosys), using Platinum® Taq-hiFidelity polymerase (Invitrogen). PCR products were then electrophoresed through 2% (w/v) agarose gel and visualised by UV light.

RNA_iinterference- NG108-15 cells were transfected with varying final concentrations of small interfering RNAs (siRNAs) for mouse *ErbB4*, *Glyceraldehyde-3-phosphate dehydrogenase* (*Gapd*, positive control) and non-targeting sequence (NT, negative control) (Ambion) using varying volumes of Lipofectamine™-RNA_iMAX transfection reagent (Invitrogen) for 24hours at 37°C/5% CO₂ before total RNA was isolated.


REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION (RT-qPCR)- NG108-15 cell cDNA was synthesised as described for RT-PCR. The cDNA was amplified by PCR and levels of *ErbB4* and *Gapd* were measured in real-time.

RESULTS

- Western blotting (Figure 1) and immunofluorescence (Figure 2) were used to show that NG108-15 cells express ErbB4.





- Western blotting of NG108-15 cell protein lysate showed multiple bands, representing the full length ErbB4 protein at 180kDa and multiple cleaved forms of ErbB4. These results are consistent with previous findings of ErbB4 expression in other tissues^{4,7}.



CONCLUSIONS

- The mouse neuroblastoma x rat glioma cell line NG108-15, expresses schizophrenia candidate gene *ErbB4* which is evident both at the mRNA and protein level.
- NG108-15 cells solely express the mouse transcript of the *ErbB4* gene.
- We have shown specific knock-down of *ErbB4* with no off-target effects in NG108-15 cells.
- NG108-15 cells are therefore, a promising model cell line for the investigation of signalling pathways that are possibly aberrant in schizophrenia.

- Expression of *ErbB4* mRNA was detected by RT-PCR using PCR primers specific for either rat or mouse *ErbB4* (Figure 3). The PCR product was sequenced (Figure 4) and bioinformatics performed to confirm species specificity of the product (Figure 5).






Chromatogram showing sequence of mouse PCR product. Sequence is mouse *ErbB4* specific. Bases which are heterogeneous between species are marked with an asterisk (*).

Figure 5

F1 Product	1	ATC	3
Amplicon Seq	1	AGGCTACATGATCCATGATGACAGCCCAACAAGATATCTGATC	50
F1 Product	4	CTGTGGAGAGAACCTTTTGTGCCAGGAAAGATGGAGTCTTCAA	53
Amplicon Seq	51	CTGTGGAGAGAACCTTTTGTGCCAGGAAAGATGGAGTCTTCAA	100
F1 Product	54	CGCTTGAATGATGATGATGATGATGATGATGATGATGATGATGATG	103
Amplicon Seq	101	GCTTTAGATATCCGAGATACAGTGTCTCCAGCGTCCACCAAGGC	150
F1 Product	104	GGAGGATGATGATGATGATGATGATGATGATGATGATGATGATGATG	153
Amplicon Seq	151	GGAGGATGATGATGATGATGATGATGATGATGATGATGATGATGATG	200
F1 Product	154	CCTTGGAGAGAACCTTTTGTGCCAGGAAAGATGGAGTCTTCAA	203
Amplicon Seq	201	CCTTGGAGAGAACCTTTTGTGCCAGGAAAGATGGAGTCTTCAA	250
F1 Product	204	AAAGCCAGAAAGATTTACACACCCGACTCTGGAAA	242
Amplicon Seq	251	AAAGCCAGAAAGATTTACACACCCGACTCTGGAAA	298

Alignment of sequence from PCR product to mouse *ErbB4* transcript shows 100% sequence identity. Bases which are heterogeneous between species are highlighted in red.

- Specific knockdown of *Gapd* was optimised (Figure 6) for use as a positive control. Specific knockdown of *ErbB4* was optimised (Figure 7) for investigating ErbB4 signalling pathways. *ErbB4* expression was reduced in all samples transfected with the *ErbB4* siRNA. These samples did not show decreased expression of other genes tested (Figure 8) suggesting that there are no off-target effects.



REFERENCES

- Norton *et al.*, 2006. Evidence that interaction between neuregulin 1 and its receptor erbB4 increases susceptibility to schizophrenia. *Am J Med Genet B Neuropsychiatr Genet* 141B(1):96-101
- Silberberg *et al.*, 2006. The involvement of ErbB4 with schizophrenia: association and expression studies. *Am J Med Genet B Neuropsychiatr Genet* 141:142-148.
- Law *et al.*, 2007. Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia. *Hum Mol Genet* 16:129-141.
- Chong *et al.*, 2008. Elevated neuregulin-1 and ErbB4 protein in the prefrontal cortex of schizophrenic patients. *Schizophr Res* 100(1-3):270-80.
- Mei & Xiong 2008. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. *Nat Rev Neurosci* 9(6):437-52
- Thompson *et al.*, 2007. Widespread expression of ErbB2, ErbB3 and ErbB4 in non-human primate brain. *J Brain Res* 1139:(95-109)

ACKNOWLEDGEMENTS

This work was funded by a BBSRC industrial CASE studentship with GlaxoSmithKline. PsyRING is a collaboration between the Universities of Glasgow and Strathclyde and NHS Greater Glasgow and Clyde